
-
Mirum Pharmaceuticals NasdaqGM:MIRM Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Location: 950 Tower Lane, Foster City, CA, 94404, United States | Website: https://www.mirumpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.269B
Cash
277.7M
Avg Qtr Burn
-1.712M
Short % of Float
15.85%
Insider Ownership
1.98%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LIVMARLI (Maralixibat) Details Liver disease, Progressive familial intrahepatic cholestasis | Approved Quarterly sales | |
CTEXLI™ (chenodiol) Tablets Details Cerebrotendinous xanthomatosis | Approved Quarterly sales | |
LIVMARLI (Maralixibat) Details ALGS (Alagille syndrome), PFIC (Progressive Familial Intrahepatic Cholestasis) | Approved Quarterly sales | |
Volixibat Details Primary biliary cholangitis, Liver disease | Phase 2b Data readout | |
Volixibat Details Liver disease, Primary sclerosing cholangitis | Phase 2b Update | |
MRM-3379 Details Fragile X syndrome | Phase 2 Initiation | |
Volixibat Details Liver disease, Intrahepatic Cholestasis of Pregnancy | Failed Discontinued | |
LIVMARLI (Maralixibat) Details Rare diseases, Bile duct disease | Failed Discontinued |